| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/17/2003 | CA2467829A1 Feminine care products for the delivery of therapeutic substances |
| 07/17/2003 | CA2467083A1 Viral capsid assembly intermediates |
| 07/16/2003 | EP1327452A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics |
| 07/16/2003 | EP1327149A2 Methods of high-throughput screening for internalizing antibodies |
| 07/16/2003 | EP1327003A2 Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products |
| 07/16/2003 | EP1326986A2 Regulation of human sphingosine kinase-like protein |
| 07/16/2003 | EP1326978A2 Hematopoietin receptors hpr1 and hpr2 |
| 07/16/2003 | EP1326972A2 Transporters and ion channels |
| 07/16/2003 | EP1326892A2 Compositions that inhibit proliferation of cancer cells |
| 07/16/2003 | EP1326891A1 Gene encoding a human g-protein coupled receptor and its use |
| 07/16/2003 | EP1326864A2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 07/16/2003 | EP1326863A2 Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines |
| 07/16/2003 | EP1326861A1 Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| 07/16/2003 | EP1326858A2 Piperidine compounds as anti-allergic |
| 07/16/2003 | EP1326851A1 Substituted dipeptides as growth hormone secretagogues |
| 07/16/2003 | EP1326840A2 Substituted heterocyclic compounds for treating multidrug resistance |
| 07/16/2003 | EP1326825A2 Compounds and compositions for delivering active agents |
| 07/16/2003 | EP1326643A2 Inhibition of emetic effect of metformin with 5-ht3 receptor antagonists |
| 07/16/2003 | EP1326642A2 Catecholamine pharmaceutical compositions and methods |
| 07/16/2003 | EP1326639A1 Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol |
| 07/16/2003 | EP1326632A2 Agents for the treatment of viral infections |
| 07/16/2003 | EP1326630A2 Use of glp-1 and glp-2 peptides |
| 07/16/2003 | EP1326629A2 Methods and compositions for promoting the maturation of monocytes |
| 07/16/2003 | EP1326626A2 Methods for treating rheumatoid arthritis using il-17 antagonists |
| 07/16/2003 | EP1326622A1 Compositions and methods for treatment of multiple myeloma |
| 07/16/2003 | EP1326621A2 Medicinal composition and in particular its use in fluid therapy |
| 07/16/2003 | EP1326618A2 Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
| 07/16/2003 | EP1326611A1 Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors |
| 07/16/2003 | EP1326608A1 Stable compositions of oxapenem-3-carboxylic acids by co-lyophilisation with pharmaceutical carriers |
| 07/16/2003 | EP1326606A2 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 07/16/2003 | EP1326605A1 Methods for inhibiting proliferation and inducing apoptosis in cancer cells |
| 07/16/2003 | EP1326604A2 Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups |
| 07/16/2003 | EP1326603A1 Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension |
| 07/16/2003 | EP1326597A2 Methods for modulating bladder function |
| 07/16/2003 | EP1326595A2 Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders |
| 07/16/2003 | EP1326594A2 Ribavirin-pegylated interferon alfa hcv combination therapy |
| 07/16/2003 | EP1326591A2 Combination of statins and sorbitol dehydrogenase inhibitors |
| 07/16/2003 | EP1326584A1 Delivery system and method of treating or preventing otitis media |
| 07/16/2003 | EP1326583A1 Medication delivery devices |
| 07/16/2003 | EP1326502A2 Method for preparing a mixture that can be granulated and carnitine-magnesium hydroxycitrate |
| 07/16/2003 | EP1253933B1 Use of neurotoxins in medicaments for thyroid disorders |
| 07/16/2003 | EP0832076B1 Novel isoxazoline and isoxazole fibrinogen receptor antagonists |
| 07/16/2003 | EP0814793B1 Prilocaine and hydrofluorocarbon aerosol preparations |
| 07/16/2003 | CN1430728A Modulation of T-cell receptor interactions |
| 07/16/2003 | CN1430675A Use of baculovirus vectors in gene therapy |
| 07/16/2003 | CN1430607A Benzophenones as inhibitors of IL-1 beta and TNF-alpha |
| 07/16/2003 | CN1430519A Combinations of enzyme inhibitor-containing preparations and the use thereof |
| 07/16/2003 | CN1430516A Crystal structures of P-selectin, P-and E-selectin complexes and use thereof |
| 07/16/2003 | CN1430512A Modulation of bone formation |
| 07/16/2003 | CN1430511A Method of improving survival of patients |
| 07/16/2003 | CN1430505A Microspheres for active embolization |
| 07/16/2003 | CN1430502A Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds |
| 07/16/2003 | CN1430496A Methods of pre-selecting polymerizable fluid formed into intraocular lens |
| 07/16/2003 | CN1429624A Lung cancer transgene vaccine and its preparation method |
| 07/16/2003 | CN1429623A Method for treating endothelium wond |
| 07/16/2003 | CN1429556A Muscle strong agent and anti-inflammatory agent |
| 07/16/2003 | CN1429551A Treating diabetes by thiazolidine-diketo and dimethylbiguanide |
| 07/16/2003 | CN1114447C Pharmaceutical antiviral compsn. comprising glycyrrhizic acid and at least one protein endowed with activiral activity |
| 07/16/2003 | CN1114404C Treatment of diabetes with thiazolidinedione and melbine |
| 07/16/2003 | CN1114403C Vitronectin receptor antagonists |
| 07/15/2003 | US6593368 Combination with NMDA receptor antagonists, NSAIDs, and analgesics. |
| 07/15/2003 | US6593362 Non-peptidic cyclophilin binding compounds and their use |
| 07/15/2003 | US6593359 Use of a RAR-γ-specific agonist ligand for increasing the rate of apoptosis |
| 07/15/2003 | US6593357 Treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease. |
| 07/15/2003 | US6593353 p53 inhibitors and therapeutic use of the same |
| 07/15/2003 | US6593347 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 07/15/2003 | US6593344 These substances have especially high cytostatic activities and pronounced immunosuppressive properties which make them suitable for therapeutic treatment in broad tumor spectrum and autoimmune diseases |
| 07/15/2003 | US6593339 Use of compounds as antibacterial agents |
| 07/15/2003 | US6593337 Tricyclic compounds useful as HIV reverse transcriptase inhibitors |
| 07/15/2003 | US6593336 Methods for treating irritable bowel syndrome |
| 07/15/2003 | US6593327 Compounds and compositions as protease inhibitors |
| 07/15/2003 | US6593321 Compounds to inhibit undesired cell proliferation and tumor growth. Additionally, methods are disclosed of treating diseases associated with undesired angiogenesis and undesired proliferation, and methods of treating infectious disease |
| 07/15/2003 | US6593319 Fusidic acid derivatives |
| 07/15/2003 | US6593313 Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunction |
| 07/15/2003 | US6593310 Add to a mammal in need of such treatment an effective amount, typically in the range of 0.1 to 100 micrograms per kg of body weight, of a compound capable of maintaining the integrity of connective tissue, for example pentosan polysulfate. |
| 07/15/2003 | US6593307 To antagonize cyclicADPRibose induced calcium release in a cell by contacting the cell with compound of invention |
| 07/15/2003 | US6593303 Anti-tumor synergetic composition |
| 07/15/2003 | US6593292 Amidine and/or guanidine substituted peptoid and drug conjugates for drug delivery across endo/epithelial tissue |
| 07/15/2003 | US6593291 Inhibition of endothelial cell proliferation inhibits neovascularization |
| 07/15/2003 | US6593290 Treatment of inner ear hair cells |
| 07/15/2003 | US6593121 Nucleotide sequences coding enzymatic polypeptide for use in the treatment of nervous system disorders |
| 07/15/2003 | US6593108 Nucleic acid molecule encoding a melanin-concentrating hormone receptor 2 polypeptide |
| 07/15/2003 | US6593094 Compositions to enhance the efficacy and safety of bio-pharmaceutical drugs |
| 07/15/2003 | US6592908 Nutritional or therapeutic compositions |
| 07/15/2003 | US6592901 Highly compressible ethylcellulose for tableting |
| 07/15/2003 | US6592894 Hydrogel-isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules |
| 07/15/2003 | US6592879 Sacrificial enzyme substrate system, an enzyme inhibitor system or mixtures or combinations thereof, where the composition reduces skin irritation due to enzyme activity. |
| 07/15/2003 | US6592862 Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 07/15/2003 | US6592848 Ready to use aerosol packages |
| 07/15/2003 | CA2262269C Treatment of skeletal disorders |
| 07/10/2003 | WO2003056029A2 Highly sensitive and continuous protein-tyrosine-phosphatase (ptpase) test using 6,8 difluoro-4-methyl-umbelliferylphosphate |
| 07/10/2003 | WO2003056012A1 A system for stable expression of sirnas in mammalian cells |
| 07/10/2003 | WO2003056006A1 Method of detecting mutation in human serotonin receptor subtype 2b gene |
| 07/10/2003 | WO2003055991A1 Igamete recruitment and developmental competence in mammals by inhibiting the de novo sterol biosynthesis and/or promoting sterol efflux |
| 07/10/2003 | WO2003055980A2 Il-17 like molecules and uses thereof |
| 07/10/2003 | WO2003055915A2 Human netrin receptor and uses thereof |
| 07/10/2003 | WO2003055913A2 Secreted protein |
| 07/10/2003 | WO2003055912A2 Secreted proteins |
| 07/10/2003 | WO2003055910A1 Beta-amyloid binding factors and inhibitors thereof |
| 07/10/2003 | WO2003055882A1 Pyrrolopyrimidines as phosphodiesterase vii inhibitors |